IBDEI0GM ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8036,0)
 ;;=173.11^^52^577^53
 ;;^UTILITY(U,$J,358.3,8036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8036,1,3,0)
 ;;=3^Eyelid/Canthus,BCC
 ;;^UTILITY(U,$J,358.3,8036,1,4,0)
 ;;=4^173.11
 ;;^UTILITY(U,$J,358.3,8036,2)
 ;;=^340467
 ;;^UTILITY(U,$J,358.3,8037,0)
 ;;=173.12^^52^577^57
 ;;^UTILITY(U,$J,358.3,8037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8037,1,3,0)
 ;;=3^Eyelid/Canthus,SCC
 ;;^UTILITY(U,$J,358.3,8037,1,4,0)
 ;;=4^173.12
 ;;^UTILITY(U,$J,358.3,8037,2)
 ;;=^340468
 ;;^UTILITY(U,$J,358.3,8038,0)
 ;;=173.19^^52^577^55
 ;;^UTILITY(U,$J,358.3,8038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8038,1,3,0)
 ;;=3^Eyelid/Canthus,Malig Neopl,Oth
 ;;^UTILITY(U,$J,358.3,8038,1,4,0)
 ;;=4^173.19
 ;;^UTILITY(U,$J,358.3,8038,2)
 ;;=^340469
 ;;^UTILITY(U,$J,358.3,8039,0)
 ;;=053.20^^52^577^51
 ;;^UTILITY(U,$J,358.3,8039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8039,1,3,0)
 ;;=3^Eyelid,Herpes Zoster
 ;;^UTILITY(U,$J,358.3,8039,1,4,0)
 ;;=4^053.20
 ;;^UTILITY(U,$J,358.3,8039,2)
 ;;=^56937
 ;;^UTILITY(U,$J,358.3,8040,0)
 ;;=054.41^^52^577^50
 ;;^UTILITY(U,$J,358.3,8040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8040,1,3,0)
 ;;=3^Eyelid,Herpes Simplex
 ;;^UTILITY(U,$J,358.3,8040,1,4,0)
 ;;=4^054.41
 ;;^UTILITY(U,$J,358.3,8040,2)
 ;;=^266563
 ;;^UTILITY(U,$J,358.3,8041,0)
 ;;=078.0^^52^577^77
 ;;^UTILITY(U,$J,358.3,8041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8041,1,3,0)
 ;;=3^Molluscum Contagiosum
 ;;^UTILITY(U,$J,358.3,8041,1,4,0)
 ;;=4^078.0
 ;;^UTILITY(U,$J,358.3,8041,2)
 ;;=^78675
 ;;^UTILITY(U,$J,358.3,8042,0)
 ;;=228.1^^52^577^76
 ;;^UTILITY(U,$J,358.3,8042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8042,1,3,0)
 ;;=3^Lymphangioma
 ;;^UTILITY(U,$J,358.3,8042,1,4,0)
 ;;=4^228.1
 ;;^UTILITY(U,$J,358.3,8042,2)
 ;;=^72391
 ;;^UTILITY(U,$J,358.3,8043,0)
 ;;=238.2^^52^577^3
 ;;^UTILITY(U,$J,358.3,8043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8043,1,3,0)
 ;;=3^Benign Neopl,Oth & Unspec Sites/Tissue
 ;;^UTILITY(U,$J,358.3,8043,1,4,0)
 ;;=4^238.2
 ;;^UTILITY(U,$J,358.3,8043,2)
 ;;=^267777
 ;;^UTILITY(U,$J,358.3,8044,0)
 ;;=242.00^^52^577^61
 ;;^UTILITY(U,$J,358.3,8044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8044,1,3,0)
 ;;=3^Goiter Toxic Dif/Graves Thyrotoxic Exoph
 ;;^UTILITY(U,$J,358.3,8044,1,4,0)
 ;;=4^242.00
 ;;^UTILITY(U,$J,358.3,8044,2)
 ;;=^267793
 ;;^UTILITY(U,$J,358.3,8045,0)
 ;;=272.2^^52^577^101
 ;;^UTILITY(U,$J,358.3,8045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8045,1,3,0)
 ;;=3^Xanthelasma
 ;;^UTILITY(U,$J,358.3,8045,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,8045,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,8046,0)
 ;;=360.40^^52^577^60
 ;;^UTILITY(U,$J,358.3,8046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8046,1,3,0)
 ;;=3^Globe/Eye Degenerative,Unspec
 ;;^UTILITY(U,$J,358.3,8046,1,4,0)
 ;;=4^360.40
 ;;^UTILITY(U,$J,358.3,8046,2)
 ;;=^268563
 ;;^UTILITY(U,$J,358.3,8047,0)
 ;;=360.42^^52^577^65
 ;;^UTILITY(U,$J,358.3,8047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8047,1,3,0)
 ;;=3^Hypertensive Blind/Absolute Glaucoma
 ;;^UTILITY(U,$J,358.3,8047,1,4,0)
 ;;=4^360.42
 ;;^UTILITY(U,$J,358.3,8047,2)
 ;;=^268565
 ;;^UTILITY(U,$J,358.3,8048,0)
 ;;=360.89^^52^577^59
 ;;^UTILITY(U,$J,358.3,8048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8048,1,3,0)
 ;;=3^Globe D/O,Other
 ;;^UTILITY(U,$J,358.3,8048,1,4,0)
 ;;=4^360.89
 ;;^UTILITY(U,$J,358.3,8048,2)
 ;;=^268581
 ;;^UTILITY(U,$J,358.3,8049,0)
 ;;=373.01^^52^577^5
 ;;^UTILITY(U,$J,358.3,8049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8049,1,3,0)
 ;;=3^Blepharitis,Ulcerative
 ;;^UTILITY(U,$J,358.3,8049,1,4,0)
 ;;=4^373.01
